BP C2
Alternative Names: Ammonium molybdate complexed with a lignin-derived polymer containing benzene polycarboxylic acids; BP-C2Latest Information Update: 28 Nov 2024
At a glance
- Originator Meabco
- Class Antineoplastics; Heavy metals; Polyphenols; Radioprotectives
- Mechanism of Action Free radical scavengers; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Chemotherapy-induced damage
- Phase I Prostate cancer
- No development reported Acute radiation syndrome; Radiation injuries
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for preclinical development in Acute-radiation-syndrome in Denmark (PO)
- 28 Dec 2021 No recent reports of development identified for preclinical development in Radiation-injuries(Prevention) in Denmark (PO)
- 15 Oct 2020 Meabco's technology platform BP-Cx-1 has patent protection worldwide